This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids (KB003-04)

This study has been completed.
Information provided by (Responsible Party):
KaloBios Pharmaceuticals Identifier:
First received: May 16, 2012
Last updated: January 30, 2015
Last verified: January 2015
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.

Condition Intervention Phase
Moderate-to-Severe Asthma Biological: Anti-GM-CSF Monoclonal Antibody 400mg Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Further study details as provided by KaloBios Pharmaceuticals:

Primary Outcome Measures:
  • Change in Percent Predicted FEV1 at Week 24 [ Time Frame: Baseline to Week 24 ]

Secondary Outcome Measures:
  • To Evaluate the Efficacy of KB003 as Measured by Asthma Exacerbation Rate [ Time Frame: Week 24 ]
  • To Evaluate the Effect of KB003 on Peak Expiratory Flow (PEF) [ Time Frame: Week 24 ]
  • To Evaluate the Safety and Tolerability of KB003 as Measured by Frequency and Severity of AEs, Clinical Safety, Laboratory Abnormalities and Chest Radiographic Assessments [ Time Frame: Week 24 ]

Enrollment: 160
Study Start Date: July 2012
Study Completion Date: January 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anti-GM-CSF Monoclonal Antibody 400mg Biological: Anti-GM-CSF Monoclonal Antibody 400mg
Anti-GM-CSF Monoclonal Antibody 400mg
Placebo Comparator: Normal Saline Other: Placebo
Normal Saline


Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • A diagnosis of asthma established for at least 2 years
  • Symptomatic asthma as defined by the Juniper Asthma Control Questionnaire
  • Symptomatic asthma despite stable treatment with inhaled corticosteroids fluticasone or budesonide, or other corticosteroids, for at least 12 weeks
  • Currently receiving inhaled long-acting beta agonist (LABA) or previously documented LABA intolerability or lack of responsiveness
  • At least 2 exacerbations (no more than 6) in the previous 12 months that required systemic corticosteroids or at least a doubling of daily oral dose

Key Exclusion Criteria:

  • Acute asthma worsening (requiring emergency room visit, hospitalization, urgent care, physician visit, or change in asthma medications) or lower respiratory tract infection requiring the use of antibiotics, within 4 weeks prior to Screening Visit.
  • History of life-threatening asthma with admission to the intensive care unit requiring the use of mechanical ventilation within the past 12 months
  • Use of any immunosuppressive or immunomodulatory agents within 12 weeks or an investigational agent within 4 weeks prior to Screening Visit
  • History of any cardiovascular, neurological, hepatic, or renal condition
  • History of smoking within the past 12 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01603277

  Show 70 Study Locations
Sponsors and Collaborators
KaloBios Pharmaceuticals
Study Chair: Nestor A. Molfino, MD, MSc KaloBios Pharmaceuticals, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: KaloBios Pharmaceuticals Identifier: NCT01603277     History of Changes
Other Study ID Numbers: KB003-04
Study First Received: May 16, 2012
Results First Received: January 12, 2015
Last Updated: January 30, 2015

Keywords provided by KaloBios Pharmaceuticals:
Moderate-to-Severe Asthma

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on August 18, 2017